Unlike conventional RNA‐based approaches that merely reduce GPC3 protein levels, our CRISPR‐mediated approach targets the full excision of the GPC3 gene, paving the way for a more durable and effective therapeutic intervention against HCC. The gene discussed is GPC3; the disease is hepatocellular carcinoma.